Moteur de recherche d’entreprises européennes
Financement de l’UE (5 250 675 €) : Essais IN-Silico pour le traitement de la maladie ischémique aiguë Hor01/11/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Essais IN-Silico pour le traitement de la maladie ischémique aiguë
Stroke is the number one cause of disability in the Western world and the 3rd most common cause of death. Despite new treatment options with intra-arterial thrombectomy, still 2 out of 3 patients still have a poor outcome. The main goal of INSIST is to advance treatments of ischemic stroke and its introduction in clinical practice by realizing in silico clinical stroke trials in which stroke and treatment are modeled. We will generate virtual populations of stroke patients, generate and validate in silico models for intra-arterial thrombectomy, thrombosis and thrombolysis, and microvascular perfusion and neurological deterioration after stroke, and integrate the in silico models to realize an in silico clinical stroke trial. We are uniquely positioned by the availability of a large pool of clinical, imaging, histopathological, and outcome data from multiple recently finalized stroke trials, a large registry (totaling 4500 patients), and new trials that will start later this year (totaling 2500 patients). We will build a population model that takes this input to generate virtual populations of stroke patients addressing the wide variety of patient characteristics. We will build on existing and emerging in silico models to validate reusable models for stroke and stroke treatment with a strong interaction with experimenting modeling in laboratories. The in silico models and virtual populations will be combined to simulate clinical trials and validated by simulating and comparing finalized and currently running trials. The in silico models will be used to simulate clinical trials to evaluate effectiveness and safety of novel devices and medication, both for the device as well as the pharmacological industry. For the device industry, we will evaluate the optimal configuration of thrombectomy stents for reduction of thrombus fragmentation. From the perspective of the pharmacy industry, we will simulate the effect of increased TAFIa on the effectiveness of alteplase.
| 908 085 € | |
| Erasmus Universitair Medisch Centrum Rotterdam | 717 500 € |
| Institut de Recherches Internationales Servier Iris | 85 500 € |
| Katholieke Universiteit Leuven | 462 500 € |
| M.V. Lomonosov Moscow State University | 0,00 € |
| NEURAVI Ltd. | 416 275 € |
| Politecnico DI Milano | 349 600 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 568 125 € |
| UNIVERSITE DE GENEVE | 771 975 € |
| 425 365 € | |
| Universiteit Van Amsterdam | 545 750 € |
https://cordis.europa.eu/project/id/777072
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Medisch Centrum BIJ DE Universiteit Van Amsterdam - Financement de l’UE (5 250 675 €) : Essais IN-Silico pour le traitement de la maladie ischémique aiguë"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
